Loading clinical trials...
Loading clinical trials...
A Phase III, Multicentre, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Conditions
Interventions
MCI-196
Another Phosphate binder (Sevelamer)
Locations
115
Austria
Graz, Austria
Frýdek-Místek, Czechia
Hradec Králové, Czechia
Ostrava, Czechia
Prague, Czechia
Tábor, Czechia
Start Date
November 1, 2007
Primary Completion Date
August 1, 2010
Completion Date
August 1, 2010
Last Updated
January 7, 2026
NCT07547098
NCT06446739
NCT07232537
NCT06278207
NCT07493642
NCT07241390
Lead Sponsor
Tanabe Pharma Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions